An investigation on behalf of investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares over potential securities laws violations by Fulcrum Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) concerning whether a series of statements by Fulcrum Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. On July 17, 2019, Fulcrum Therapeutics, Inc announced the pricing of its initial public offering (IPO) of 4.5 million shares at $16.00 per share, for gross proceeds of $72.0 million.

However, since the IPO shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) declined to $6.27 per share on October 3, 2019.